Allogene Therapeutics
Hsin-Yuan Cheng is a Senior Principal Scientist at Allogene Therapeutics since December 2018, previously holding the position of Principal Scientist. Prior experience includes a Scientist role at Compugen from June 2015 to November 2018, focusing on in vitro assay development and expression analysis, as well as in vivo and ex vivo studies. Hsin-Yuan served as a Postdoctoral Fellow at the La Jolla Institute for Allergy and Immunology from April 2010 to May 2015, conducting research on the regulation of Tregs in atherosclerosis and the impact of cholesterol on T cell differentiation. Educational qualifications include a Ph.D. in Cell and Molecular Physiology from the University of North Carolina at Chapel Hill, a Master's in Molecular Medicine from National Taiwan University, and a Bachelor's Degree in Agricultural Chemistry, also from National Taiwan University.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.